Q4 2022 Earnings Estimate for Alnylam Pharmaceuticals, Inc. Issued By SVB Leerink (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) – Stock analysts at SVB Leerink lifted their Q4 2022 earnings per share estimates for Alnylam Pharmaceuticals in a research report issued on Thursday, August 4th. SVB Leerink analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings per share of $0.24 for the quarter, up from their previous estimate of $0.23. SVB Leerink has a “Market Perform” rating and a $98.00 price target on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($7.85) per share.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.67). The company had revenue of $224.80 million during the quarter, compared to analysts’ expectations of $256.06 million. Alnylam Pharmaceuticals had a negative return on equity of 204.18% and a negative net margin of 110.91%. The company’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.61) EPS.

Several other analysts also recently issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 12th. They issued a “neutral” rating and a $175.00 price objective for the company. HC Wainwright raised their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $430.00 in a research note on Monday, May 2nd. Guggenheim downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, June 27th. Morgan Stanley lifted their price target on shares of Alnylam Pharmaceuticals from $159.00 to $225.00 and gave the company an “equal weight” rating in a research note on Thursday. Finally, BMO Capital Markets lifted their price target on shares of Alnylam Pharmaceuticals from $166.00 to $192.00 and gave the company a “market perform” rating in a research note on Thursday. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $225.75.

Alnylam Pharmaceuticals Stock Down 2.4 %

Shares of NASDAQ ALNY opened at $218.58 on Friday. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.76 and a quick ratio of 3.62. The company has a market cap of $26.24 billion, a P/E ratio of -26.75 and a beta of 0.74. Alnylam Pharmaceuticals has a 1 year low of $117.58 and a 1 year high of $226.00. The firm has a 50-day simple moving average of $145.22 and a two-hundred day simple moving average of $147.90.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC grew its holdings in Alnylam Pharmaceuticals by 5.8% in the first quarter. Kestra Advisory Services LLC now owns 1,339 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 74 shares during the last quarter. Signaturefd LLC grew its holdings in Alnylam Pharmaceuticals by 8.1% in the first quarter. Signaturefd LLC now owns 998 shares of the biopharmaceutical company’s stock worth $163,000 after purchasing an additional 75 shares during the last quarter. MUFG Americas Holdings Corp grew its holdings in Alnylam Pharmaceuticals by 5.3% in the fourth quarter. MUFG Americas Holdings Corp now owns 1,755 shares of the biopharmaceutical company’s stock worth $298,000 after purchasing an additional 89 shares during the last quarter. CKW Financial Group grew its holdings in Alnylam Pharmaceuticals by 50.0% in the first quarter. CKW Financial Group now owns 300 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 100 shares during the last quarter. Finally, Commerce Bank grew its holdings in Alnylam Pharmaceuticals by 2.3% in the first quarter. Commerce Bank now owns 4,358 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 100 shares during the last quarter. 92.39% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Tolga Tanguler sold 1,754 shares of the business’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $210.00, for a total value of $368,340.00. Following the completion of the transaction, the executive vice president now owns 3,629 shares of the company’s stock, valued at $762,090. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 5,349 shares of company stock valued at $1,033,073 over the last 90 days. Corporate insiders own 1.40% of the company’s stock.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Stories

• Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
• MarketBeat: Week in Review 8/1 – 8/5
• How to Use High Beta Stocks to Maximize Your Investing Profits
• Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
• Beyond Meat Is Not Beyond Hope, And It’s Cheap
• Why Apple Could Be At All-Time Highs By Year End

Want More Great Investing Ideas?